AGM/EGMJun 17, 2026, 04:07 PM
Insight Molecular Diagnostics Shareholders Approve 1.75M Share Increase for Equity Plan
AI Summary
Insight Molecular Diagnostics Inc. held its 2026 Annual Meeting of Shareholders on June 11, 2026, where key proposals were approved. Shareholders voted to amend the 2018 Equity Incentive Plan, increasing the total number of authorized shares for issuance by 1,750,000 to 5,550,000. Additionally, four director nominees were elected, CBIZ CPAs P.C. was ratified as the independent auditor for 2026, and the named executive officer compensation for 2025 was approved on an advisory basis.
Key Highlights
- Shareholders approved an amendment to the 2018 Equity Incentive Plan, increasing authorized shares by 1,750,000 to a total of 5,550,000.
- Four director nominees (Joshua Riggs, Andrew Arno, Andrew J. Last, Louis E. Silverman) were elected to serve until the 2027 annual meeting.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- The Company's named executive officer compensation for 2025 was approved on a non-binding advisory basis.
- The Annual Meeting, held on June 11, 2026, had 74.19% of the voting power represented by 23,954,212 shares.
Price Impact
More from IMDX